

## Appendix 4E

### Preliminary Final Report

#### 1. Company details

Name of entity

**Pro Medicus Limited**

ABN or equivalent  
company reference

**25 006 194 752**

Financial year ended  
(‘current period’)

**30 June 2016**

Financial year ended  
(‘previous period’)

**30 June 2015**

#### 2. Results for announcement to the market

ASX Listing Rules Ref		2016 A\$'000	2015 A\$'000	% change
2.1	Revenue from continuing operations	27,577	17,577	56.9%
2.2	Underlying Profit after Tax (minus currency gains/(losses))	6,431	2,063	211.7%
	Currency gains/(losses) after tax	(63)	1,154	N/A
	Profit/(Loss) from ordinary activities after tax attributable to members	6,368	3,217	97.9%
2.3	Net Profit/(Loss) for the period attributable to members	6,368		
	% change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.	Up 97.9%		

2.4	Dividends (distributions)	Amount per security	Unfranked amount per security
	Unfranked dividend amount per security		
	Final Dividend	1.5 cents	1.5 cents
	Interim dividend	1.5 cents	1.5 cents
2.5	Record date for Final dividends	9 September 2016	
	Payment date for Final dividends	29 September 2016	

<p><b>2.6</b></p>	<p><u>Australia</u></p> <p>The Group's Australian employees undertake research and development of Pro Medicus products (RIS) as well as sales and service/support functions.</p> <p>The Group's Australian revenue was 3.6% above last year as a result of new sales of both the Visage PACS and Visage RIS products with many sales being for the combined product offering.</p> <p>Promedicus.net, the company's e-health offering, continued to hold its market position despite increasing competition.</p> <p><u>North America</u></p> <p>The growing North American team fulfil sales, marketing and professional services roles. Revenue from North America increased by 90.0% compared to the previous year. This was largely attributable to new sales and an increase in transaction based revenue from sales of Visage technology as more contracts came on stream.</p> <p><u>Europe</u></p> <p>The Group's employees in its Berlin office undertake research and development of Visage Imaging products worldwide as well as sales, marketing and service/support functions for the Group's European operations. Revenue from our European operations increased by 77.1% from last year, due to a large capital sale to a German government hospital.</p> <p><u>Financials</u></p> <p>Reported profit after tax for the period was \$6.37m an increase of \$3.15m (97.9%) from the previous year.</p> <p>Full year revenue of the Group increased from \$17.58m to \$27.58m, an increase of 56.9%.</p> <p>The key drivers of the profit increase was the significant increase in the performance of the North American operations which was supplemented by a capital sale in Europe and a modest increase in Australian sales.</p> <p>As the Group's costs are relatively fixed, an increase in sales has a positive impact on profitability.</p> <p>As a result, it is anticipated that the 2017 financial year will show a continuing improvement in operational results, however this is dependent upon many market factors over which the Directors have limited or no control.</p> <p><u>Shareholder Returns</u></p> <p>The directors are confident that the holdings of reserve cash are sufficient to underpin the development and expansion needs of the company as the business looks to increase its penetration of existing markets.</p>
<p><b>9</b></p>	<p><b>Statement of Comprehensive Income</b></p> <p>Please refer to the Statement of Comprehensive Income in the attached Financial Statements.</p>
<p><b>4.</b></p>	<p><b>Statement of Financial Position</b></p> <p>Please refer to the Statement of Financial Position in the attached Financial Statements.</p>
<p><b>5.</b></p>	<p><b>Statement of cash flows</b></p> <p>Please refer to the Statement of cash flows in the attached Financial Statements.</p>

<b>6.</b>	<p><b>Details of Dividends</b></p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="text-align: right; width: 15%;">2016 \$'000</th> <th style="text-align: right; width: 15%;">2015 \$'000</th> </tr> </thead> <tbody> <tr> <td><b>Final Dividend</b></td> <td></td> <td></td> </tr> <tr> <td>An unfranked Final Dividend of 1.5 cents (2015: 1.0 cents) per share will be paid on 30 September 2016.</td> <td style="text-align: right;">1,526</td> <td style="text-align: right;">1,002</td> </tr> <tr> <td><b>Current Year Interim</b></td> <td></td> <td></td> </tr> <tr> <td>An unfranked Interim Dividend of 1.5 cents (2015: 1.0 cents) per share was paid on 24 March 2016.</td> <td style="text-align: right;">1,526</td> <td style="text-align: right;">1,002</td> </tr> <tr> <td colspan="3">No foreign sourced dividend or distribution is included in either the interim or final dividends.</td> </tr> </tbody> </table>		2016 \$'000	2015 \$'000	<b>Final Dividend</b>			An unfranked Final Dividend of 1.5 cents (2015: 1.0 cents) per share will be paid on 30 September 2016.	1,526	1,002	<b>Current Year Interim</b>			An unfranked Interim Dividend of 1.5 cents (2015: 1.0 cents) per share was paid on 24 March 2016.	1,526	1,002	No foreign sourced dividend or distribution is included in either the interim or final dividends.		
	2016 \$'000	2015 \$'000																	
<b>Final Dividend</b>																			
An unfranked Final Dividend of 1.5 cents (2015: 1.0 cents) per share will be paid on 30 September 2016.	1,526	1,002																	
<b>Current Year Interim</b>																			
An unfranked Interim Dividend of 1.5 cents (2015: 1.0 cents) per share was paid on 24 March 2016.	1,526	1,002																	
No foreign sourced dividend or distribution is included in either the interim or final dividends.																			
<b>7.</b>	<p><b>Dividend or Distribution reinvestment plans</b></p> <p>There are no dividend or distribution reinvestment plans in operation.</p>																		
<b>8.</b>	<p><b>Statement of Retained Earnings</b></p> <p>Please refer to Statement of Changes in Equity in the attached Financial Statements.</p>																		
<b>9.</b>	<table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="text-align: right; width: 15%;">2016</th> <th style="text-align: right; width: 15%;">2015</th> </tr> </thead> <tbody> <tr> <td><b>Net Tangible Assets per security</b></td> <td></td> <td></td> </tr> <tr> <td>Net Tangible Assets per security</td> <td style="text-align: right;"><b>\$0.17</b></td> <td style="text-align: right;">\$0.13</td> </tr> </tbody> </table>		2016	2015	<b>Net Tangible Assets per security</b>			Net Tangible Assets per security	<b>\$0.17</b>	\$0.13									
	2016	2015																	
<b>Net Tangible Assets per security</b>																			
Net Tangible Assets per security	<b>\$0.17</b>	\$0.13																	
<b>10.</b>	<p><b>Details of entities over which control has been gained or lost during the period</b></p> <p>There are no entities over which control has been gained or lost during the period</p>																		
<b>11.</b>	<p><b>Associates and joint venture entities</b></p> <p>There are no associates or joint venture entities</p>																		
<b>12.</b>	<p><b>Other significant information needed by an investor to make an informed assessment of the entity's financial performance and financial position.</b></p> <p>Please refer to section 2.6</p>																		
<b>13.</b>	<p><b>Foreign Entity accounting standards</b></p> <p>Australian Accounting Standards &amp; International Financial Reporting Standards</p>																		

14.	<p><b>Commentary on results for the period.</b> <b>The earnings per security and the nature of any dilution aspects.</b> Please refer to Note 8 of the attached Financial Statements.</p> <p><b>Returns to shareholders including distributions and buy backs.</b> Please refer to Note 9 of the attached Financial Statements.</p> <p><b>Significant features of operating performance.</b> Please refer to section 2.6.</p> <p><b>The results of segments that are significant to an understanding of the business.</b> Please refer to Note 5 of the attached Financial Statements.</p> <p><b>Discussion of trends in performance.</b> Please refer to section 2.6.</p>
15.	<p><b>Audit Statement</b></p> <p>This report is based on accounts to which one of the following applies. (Tick one)</p> <p><input checked="" type="checkbox"/> The *accounts have been audited. <input type="checkbox"/> The *accounts have been subject to review.</p> <p><input type="checkbox"/> The *accounts are in the process of being audited. <input type="checkbox"/> The *accounts have <i>not</i> yet been audited or reviewed.</p>

Sign here:

Date: 19 August 2016



Print name: Sam Hupert  
Chief Executive Officer